Your browser is no longer supported. Please, upgrade your browser.
VNDA Vanda Pharmaceuticals Inc. daily Stock Chart
Vanda Pharmaceuticals Inc.
Index- P/E5.02 EPS (ttm)2.09 Insider Own0.70% Shs Outstand54.50M Perf Week-6.35%
Market Cap586.01M Forward P/E237.95 EPS next Y0.04 Insider Trans-9.62% Shs Float52.89M Perf Month6.29%
Income113.80M PEG- EPS next Q0.10 Inst Own98.00% Short Float11.27% Perf Quarter-3.68%
Sales240.60M P/S2.44 EPS this Y343.30% Inst Trans0.17% Short Ratio9.83 Perf Half Y-7.51%
Book/sh7.92 P/B1.32 EPS next Y-88.17% ROA23.30% Target Price18.33 Perf Year-22.96%
Cash/sh6.07 P/C1.72 EPS next 5Y- ROE27.40% 52W Range7.12 - 17.85 Perf YTD-36.20%
Dividend- P/FCF15.42 EPS past 5Y30.80% ROI26.60% 52W High-41.34% Beta0.56
Dividend %- Quick Ratio6.20 Sales past 5Y35.30% Gross Margin90.00% 52W Low47.05% ATR0.42
Employees284 Current Ratio6.20 Sales Q/Q5.20% Oper. Margin10.00% RSI (14)50.79 Volatility4.19% 3.92%
OptionableYes Debt/Eq0.00 EPS Q/Q-25.10% Profit Margin47.30% Rel Volume0.47 Prev Close10.79
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout0.00% Avg Volume606.55K Price10.47
Recom2.00 SMA203.65% SMA500.50% SMA200-8.01% Volume284,939 Change-2.97%
Jun-09-20Downgrade Citigroup Buy → Neutral $14
Mar-16-20Downgrade Oppenheimer Perform → Underperform
Mar-12-20Upgrade Citigroup Neutral → Buy $14
Nov-07-19Downgrade Citigroup Buy → Neutral $19
Aug-01-19Upgrade Citigroup Neutral → Buy $19
Jul-25-19Downgrade Stifel Buy → Hold $26 → $17
Dec-11-18Downgrade Oppenheimer Outperform → Perform
Dec-04-18Upgrade Cantor Fitzgerald Neutral → Overweight
Dec-04-18Reiterated Jefferies Buy $30 → $40
Nov-08-18Resumed Jefferies Buy
Sep-21-18Resumed Oppenheimer Outperform
May-23-18Initiated Citigroup Buy $26
Jan-19-18Initiated Seaport Global Securities Buy $20
Sep-14-17Reiterated Piper Jaffray Overweight $23 → $26
Jun-27-17Resumed Piper Jaffray Overweight $23
May-26-17Initiated H.C. Wainwright Buy $18
Apr-12-17Initiated Oppenheimer Outperform $21
Nov-09-16Initiated Aegis Capital Buy $24
Oct-06-16Resumed Jefferies Buy
Jan-09-15Initiated Canaccord Genuity Buy $22
Oct-13-20 01:14PM  
Oct-02-20 01:44PM  
Sep-15-20 03:41PM  
Aug-31-20 06:30PM  
Aug-18-20 10:24AM  
Aug-06-20 08:21PM  
Aug-05-20 06:05PM  
Aug-03-20 08:53AM  
Jul-29-20 05:00PM  
Jul-22-20 12:32PM  
Jul-21-20 04:04PM  
Jul-14-20 11:02AM  
Jul-13-20 04:30PM  
Jun-19-20 02:38PM  
May-26-20 07:00AM  
May-21-20 05:08PM  
May-20-20 05:20PM  
May-15-20 11:43AM  
May-14-20 07:03AM  
May-13-20 07:00AM  
May-08-20 07:32PM  
May-07-20 11:31AM  
May-06-20 06:45PM  
Apr-29-20 04:05PM  
Apr-27-20 02:18PM  
Apr-23-20 09:12AM  
Apr-22-20 01:01PM  
Apr-21-20 05:14PM  
Apr-17-20 10:00AM  
Apr-16-20 10:58AM  
Apr-15-20 04:15PM  
Apr-09-20 07:52AM  
Apr-08-20 04:05PM  
Apr-03-20 02:26PM  
Apr-02-20 01:36PM  
Mar-19-20 12:59PM  
Mar-10-20 05:13PM  
Feb-27-20 05:35PM  
Feb-26-20 03:05PM  
Feb-25-20 04:13PM  
Feb-21-20 12:26PM  
Feb-19-20 07:00AM  
Feb-18-20 08:22PM  
Feb-05-20 09:15AM  
Feb-03-20 03:28PM  
Jan-31-20 06:24PM  
Jan-16-20 02:57PM  
Jan-13-20 02:11PM  
Jan-12-20 03:34PM  
Dec-29-19 09:40PM  
Dec-23-19 02:27PM  
Dec-12-19 05:15PM  
Dec-10-19 09:12PM  
Nov-19-19 07:15AM  
Nov-18-19 04:01PM  
Nov-14-19 10:35AM  
Nov-07-19 07:18AM  
Nov-06-19 04:01PM  
Oct-31-19 01:25PM  
Oct-30-19 04:30PM  
Oct-28-19 04:30PM  
Oct-23-19 04:01PM  
Oct-16-19 04:01PM  
Oct-15-19 08:25AM  
Oct-10-19 01:49PM  
Sep-25-19 06:18PM  
Sep-11-19 05:20PM  
Sep-04-19 10:55AM  
Aug-28-19 08:02AM  
Aug-21-19 11:00AM  
Aug-20-19 08:34AM  
Aug-19-19 02:54PM  
Aug-13-19 03:23PM  
Aug-11-19 03:46PM  
Aug-09-19 01:35PM  
Aug-08-19 10:20AM  
Aug-05-19 03:59PM  
Aug-02-19 02:45PM  
Aug-01-19 05:36PM  
Jul-31-19 06:35PM  
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wijkstrom JoakimSVP, Chief Marketing OfficerAug 20Sale11.083,71041,10956,290Aug 21 06:08 PM
Williams TimothySVP & General CounselAug 14Sale11.813,68443,52679,356Aug 17 04:42 PM
Jones Aranthan IIChief Corp. Affairs OfficerAug 12Sale11.817,20085,01875,487Aug 14 04:39 PM
Jones Aranthan IIChief Corp. Affairs OfficerJul 27Sale10.627,31377,63182,687Jul 29 08:17 PM
Watkins ThomasDirectorMay 29Option Exercise7.3815,000110,70045,000Jun 02 04:13 PM
Watkins ThomasDirectorMay 29Sale11.509,677111,28635,323Jun 02 04:13 PM
DUGAN RICHARD WDirectorMay 28Option Exercise7.3815,000110,70050,770May 29 04:10 PM
DUGAN RICHARD WDirectorMay 28Sale11.0410,129111,80640,641May 29 04:10 PM
Kelly James PatrickEVP & Chief Financial OfficerMar 03Sale10.765,88963,359186,869Mar 04 05:01 PM
Birznieks GuntherSVP, Business DevelopmentMar 03Sale10.665,53558,984159,473Mar 04 05:00 PM
Polymeropoulos Mihael HristosPresident and CEOMar 03Sale10.985,15256,5441,278,999Mar 04 05:02 PM
Williams TimothySVP & General CounselMar 03Sale10.511,23713,00483,040Mar 04 05:03 PM
Williams TimothySVP & General CounselMar 02Sale10.303,14832,43684,277Mar 04 05:03 PM
Reverberi Gian PieroSVP & Chief Commercial OfficerMar 02Sale10.181,45014,755165,384Mar 04 05:02 PM
Polymeropoulos Mihael HristosPresident and CEOMar 02Sale10.5710,428110,2111,284,151Mar 04 05:02 PM
Birznieks GuntherSVP, Business DevelopmentMar 02Sale10.0412,223122,686165,008Mar 04 05:00 PM
Kelly James PatrickEVP & Chief Financial OfficerMar 02Sale10.1912,968132,087192,758Mar 04 05:01 PM
Polymeropoulos Mihael HristosPresident and CEOJan 02Sale16.009,467151,4931,234,579Jan 06 05:26 PM
Reverberi Gian PieroSVP & Chief Commercial OfficerJan 02Sale16.061,15518,551166,834Jan 06 05:26 PM
Kelly James PatrickEVP & Chief Financial OfficerJan 02Sale15.944,02064,086205,726Jan 06 05:25 PM
Birznieks GuntherSVP, Business DevelopmentJan 02Sale15.934,02064,021147,231Jan 06 05:25 PM
Polymeropoulos Mihael HristosPresident and CEODec 12Option Exercise10.6585,801913,7811,314,082Dec 13 04:21 PM
Polymeropoulos Mihael HristosPresident and CEODec 12Sale16.9870,0361,189,3511,244,046Dec 13 04:21 PM
Polymeropoulos Mihael HristosPresident and CEODec 11Option Exercise10.6589,199949,9691,300,654Dec 13 04:21 PM
Polymeropoulos Mihael HristosPresident and CEODec 11Sale16.9272,3731,224,3771,228,281Dec 13 04:21 PM